195 related articles for article (PubMed ID: 20431848)
1. Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms.
Cella G; Marchetti M; Vianello F; Panova-Noeva M; Vignoli A; Russo L; Barbui T; Falanga A
Thromb Haemost; 2010 Jul; 104(1):151-6. PubMed ID: 20431848
[TBL] [Abstract][Full Text] [Related]
2. Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera.
Panova-Noeva M; Marchetti M; Spronk HM; Russo L; Diani E; Finazzi G; Salmoiraghi S; Rambaldi A; Barbui T; Ten Cate H; Falanga A
Am J Hematol; 2011 Apr; 86(4):337-42. PubMed ID: 21442635
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea therapy increases plasma erythropoietin in patients with essential thrombocythaemia or polycythaemia vera.
Johansson P; Andréasson B
Clin Lab Haematol; 2006 Aug; 28(4):233-6. PubMed ID: 16898960
[TBL] [Abstract][Full Text] [Related]
5. Circulating endothelial cells and endothelial activation in essential thrombocythemia: results from CD146+ immunomagnetic enrichment--flow cytometry and soluble E-selectin detection.
Belotti A; Elli E; Speranza T; Lanzi E; Pioltelli P; Pogliani E
Am J Hematol; 2012 Mar; 87(3):319-20. PubMed ID: 22190201
[TBL] [Abstract][Full Text] [Related]
6. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
7. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
Besses C; Alvarez-Larrán A; Martínez-Avilés L; Mojal S; Longarón R; Salar A; Florensa L; Serrano S; Bellosillo B
Br J Haematol; 2011 Feb; 152(4):413-9. PubMed ID: 21219298
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
9. [Soluble P-selectin - a marker of platelet activation and vessel wall injury: increase of soluble P-selectin in plasma of patients with myocardial infarction, massive atherosclerosis and primary pulmonary hypertension].
Semenov AV; Kogan-Ponomarev MIa; Ruda MIa; Komarov AL; Panchenko EP; Chazova IE; Mazurov AV
Ter Arkh; 2000; 72(4):15-20. PubMed ID: 10833791
[TBL] [Abstract][Full Text] [Related]
10. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Colomer D; Villamor N; Bellosillo B; Cervantes F
Am J Hematol; 2009 Feb; 84(2):102-8. PubMed ID: 19105233
[TBL] [Abstract][Full Text] [Related]
11. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
12. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
13. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
14. [Selectins in the pathogenesis and diagnosis of early atherosclerotic changes in children and adolescents with risk factors (obesity, hypertension and diabetes)].
Głowińska B; Urban M; Peczyńska J; Florys B
Przegl Lek; 2004; 61(9):935-9. PubMed ID: 15803902
[TBL] [Abstract][Full Text] [Related]
15. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera.
Abdulkarim K; Ridell B; Johansson P; Kutti J; Safai-Kutti S; Andréasson B
Eur J Haematol; 2011 Feb; 86(2):148-55. PubMed ID: 21059102
[TBL] [Abstract][Full Text] [Related]
16. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
17. Comparison of coated-platelet levels in patients with essential thrombocythemia with and without hydroxyurea treatment.
Reményi G; Szász R; Debreceni IB; Szarvas M; Batár P; Nagy B; Kappelmayer J; Udvardy M
Platelets; 2013; 24(6):486-92. PubMed ID: 23216455
[TBL] [Abstract][Full Text] [Related]
18. ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.
Panova-Noeva M; Marchetti M; Russo L; Tartari CJ; Leuzzi A; Finazzi G; Rambaldi A; ten Cate H; Falanga A
Thromb Res; 2013 Jul; 132(1):88-93. PubMed ID: 23735588
[TBL] [Abstract][Full Text] [Related]
19. The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera.
Johansson P; Ricksten A; Wasslavik C; Johansson B; Andréasson B
Haematologica; 2004 Oct; 89(10):1264-6. PubMed ID: 15477215
[TBL] [Abstract][Full Text] [Related]
20. Myeloproliferative Disease: Markers of Endothelial and Platelet Status in Patients with Essential Thrombocythemia and Polycythemia Vera.
Musolino C; Alonci A; Bellomo G; Tringali O; Spatari G; Quartarone C; Rizzo V; Calabrò L; Bagnato G; Frisina N
Hematology; 2000; 4(5):397-402. PubMed ID: 11399581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
